Hamburg, Germany, March 19, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that its partner Bristol Myers Squibb (BMS) has initiated a Phase 1 clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.

Initiation of the first‑in‑human study represents a significant advancement in the strategic protein degradation collaboration, bringing into the clinic a novel CELMoD or ‘molecular glue’ candidate jointly generated through Evotec’s powerful and fully integrated drug discovery platform. This platform combines high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities, selectively prompting cancer cells to eliminate disease‑driving proteins. As a result of this clinical progression, Evotec will receive a milestone payment of $10 million.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec said:

“In this unique collaboration, we follow a systematic approach to discovering molecular glues with tremendous therapeutic potential. Together with Bristol Myers Squibb, and building on Evotec’s PanOmics and PanHunter platforms, we have identified a broad portfolio of high-potential molecular glue drug candidates that are now beginning to enter clinical development. The initiation of this Phase 1 clinical trial marks the first clinical milestone in the strategic protein degradation partnership with BMS. Molecular glues have the potential to address significant unmet medical need not only in oncology, but far beyond, by targeting previously undruggable, disease-causing proteins and thereby aiming to reshape future standards of care.“

BMS-986506 was developed under the strategic protein degradation partnership between Evotec and Bristol Myers Squibb. The collaboration combines PanOmics, Evotec’s high-performance multi-omics screening platform as well as PanHunter, Evotec’s AI-supported data omics analytics platform with BMS’s industry-leading library of CELMoDs™ agents. Initiated in 2018 and expanded in 2022, the collaboration is continuing to deliver on its goal to identify novel molecular glue degraders for high-value targets in the field of oncology and beyond.

About Molecular Glue Degraders

Conventional small molecule therapeutics work via a drug-induced interference with a protein activity. This limitation to agonistic or antagonistic functions renders about 90% of proteins “undruggable”. Conventional small molecules only work while they are actively binding to the receptor, which typically requires a treatment regimen consisting of one or even several carefully dosed medications every day.

Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and degradation of the recruited protein. This event-driven mechanism of action significantly expands the range of the druggable proteome. The molecular glue is not degraded in the process and can trigger the degradation process many times over, thus leading to longer-lasting therapeutic effects.

About Evotec’s Strategic Collaboration with Bristol Myers Squibb in Molecular Glues

In 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. BMS is a leader in this field based on its unique library of CELMoDs™ agents. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.

Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec’s leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec’s PanOmics data analysis platform PanHunter. It supports the integration and analysis of these data sets and thereby enables the selection of the most promising CELMoDs™ for further progression into lead optimization.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

Viromed Medical AG: Anna Heinen appointed to the Supervisory Board

Rellingen, March 19, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has appointed a new member to its Supervisory Board. Anna Heinen was appointed to the Supervisory Board by court order. She succeeds Frank Otto, who resigned from the Supervisory Board for personal reasons.

Dr. Thomas Gutschlag, Chairman of the Supervisory Board of Viromed Medical AG, states: “I am very pleased that we have gained a qualified Supervisory Board member in Anna Heinen with proven expertise in the areas of corporate strategy, transformation, and governance. With her experience, she will provide important impetus for the further development of our company. At the same time, on behalf of the entire Supervisory Board and the Management Board, I would like to express our sincere thanks to Frank Otto for his commitment over the past three years. He provided valuable support to Viromed during the company’s crucial growth phase.”

Anna Heinen has been a member of the Supervisory Board of Smartaxxess Operation AG, a fintech company focused on planning, valuation and financing for small and medium-sized enterprises, since 2022. She is also a qualified Supervisory Board member according to Deutsche Börse standards, as well as being a member of ARMID – Aufsichtsräte Mittelstand in Deutschland e.V. Professionally, Ms. Heinen has been responsible for the corporate strategy of e-fellows.net GmbH & Co. KG, an HR service provider owned by McKinsey & Company and Zeitverlag, for many years. Since 2023, she has also supported medium-sized companies regularly in succession and transformation processes as an independent management consultant.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de

Press contact

E-Mail: viromed@kirchhoff.de

Media release

PolyPeptide strengthens financing structure through expansion of existing credit facility

Baar, 19 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the strengthening of its financing structure through the expansion of its existing credit facility. 

PolyPeptide has expanded its existing credit facility to EUR 200 million, reinforcing its financing position. UBS continues to act as coordinator and agent of the lending syndicate, which now includes ING Bank in addition to Danske Bank and Zürcher Kantonalbank.

The expanded facility further enhances PolyPeptide’s financial flexibility as the Group advances toward its strategic objective of doubling 2023 revenue by 2028, supported by expected improvements in profitability and cash flow as well as continued customer funding for major capacity‑expansion projects. 

Juan Jose Gonzalez, CEO of PolyPeptide: “The expansion of our credit facility and the addition of ING Bank to our lending syndicate reinforce the confidence our banking partners have in PolyPeptide’s strategy and long‑term growth potential. With this increased financing capacity, we are well positioned to advance toward our ambition of doubling 2023 revenue by 2028 and to continue our growth journey from a position of solid financial strength.”

Contact

PolyPeptide Group AG
Corporate Communications
Lauren Starr
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Investor Relations
Tim Brandl
investorrelations@polypeptide.com
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.  

@PolyPeptide — follow us on LinkedIn.

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Frauenfeld, 19 March 2026

Press release

DocMorris and Google partner to advance one of Europe’s leading AI-powered digital health platform

Today, DocMorris and Google announced a partnership to accelerate DocMorris’ AI-first transformation. Under this initiative, DocMorris will utilise Google’s cutting-edge AI capabilities and secure cloud infrastructure to advance its own next-generation digital health platform, combining its deep healthcare and pharmaceutical expertise with Google’s most advanced technologies.

Transforming the patient journey through AI
The partnership will deliver seamlessly connected, AI-driven patient services for DocMorris’ customers. Key initiatives include:

• AI health companion: A personalised digital health companion using Gemini models and Google products such as YouTube and Health Connect to support patients and consumers from symptom onset to e-prescription redemption offering and end-to-end support and assistance.
• AI-enhanced online pharmacy: Deploying conversational AI to provide intuitive, personalised shopping experiences for DocMorris’ 11 million active customers.
• Enterprise productivity: Implementing Google Workspace with Gemini and agentic AI to enhance operational efficiency across DocMorris’ European markets.
• Cloud and data security: Migrating DocMorris’ entire infrastructure to Google Cloud, ensuring personal health data is processed within EU data centers and meets leading security standards.

“At its core, our transformation is all about the patient. By leveraging Google’s world-class AI infrastructure and security standards, we are empowering individuals with direct, secure access to their own health journey through a personalised and intuitive experience,” said Walter Hess, CEO of DocMorris. “We have intentionally chosen Google as our partner because they enable us to maintain full digital sovereignty while meeting the highest requirements for data privacy and security. Entrusting our data to Google Cloud ensures that our innovation is built on a foundation that is not only cutting-edge but also strictly compliant with the rigorous standards our customers expect in healthcare.”

Philipp Justus, Vice President, Google Central Europe, commented on the partnership: “AI is a powerful tool for transformation, and we are excited to support DocMorris on its journey to becoming an AI-first healthcare leader. By leveraging Google products and services including Google Cloud, our Gemini models, Google Ads and Google for Health, DocMorris is setting a new standard for a digital health ecosystem that is personalised, efficient, and secure. We look forward to redefining the future of healthcare together.”

The partnership represents a unique synergy between several teams including Google Ads, Google Cloud, and Google for Health.

Investors and analyst contact
Moritz Stahlhut, Investor Relations Manager
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,000 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Frauenfeld, 19 March 2026

Press release
Ad hoc announcement pursuant to Art. 53 LR

DocMorris achieves 2025 targets – focus on profitability, growth and expansion of digital health platform

• Revenue and earnings targets for 2025 met with growth across all business units
• Continued structural EBITDA improvement in the second half of 2025
• Cash and cash equivalents of CHF 160 million
• Partnership with Google to accelerate the implementation of the “AI First” platform strategy
• Closure of the logistics site in Ludwigshafen and integration into Heerlen
• Outlook: Management reaffirms EBITDA breakeven in the course of 2026

CEO Walter Hess says: “In the 2025 financial year, we deliberately concentrated on qualitative growth, increasing our operational efficiency, and technological differentiation. The evolution from a transaction-oriented online pharmacy business to a digital, AI-powered health platform is being further accelerated by our partnership with Google. With our AI health companion and the use of Gemini models as well as Google for Health assets, we can increase customer loyalty and address their health needs in a more personalised way. This solidifies our role as a driver of innovation and reinforces the technological foundation for sustainable profitability.”

CFO Daniel Wüest adds: “We achieved our revenue and earnings targets for 2025 and have a strong liquidity position. Particularly pleasing is the continuous structural improvement of our EBITDA in recent months, driven among other factors by the increase in marketing efficiency to support healthy Rx growth. We remain committed to our clear objective of reaching EBITDA break-even in the course of 2026 and positive free cash flow in the course of 2027.”

Structural earnings improvement in 2025

• External revenue[1] increased by 11.1 per cent in local currency to CHF 1,185.7 million. Consolidated revenue rose by 12.4 per cent in local currency to CHF 1,124.5 million.
• All segments and business units contributed to the revenue growth.
• Despite additional marketing expenses of over CHF 11 million for Rx in the first three quarters, adjusted EBITDA improved slightly from minus CHF 48.6 million to minus CHF 48.2 million, with a continuous structural improvement throughout the year. Simultaneously, the gross margin increased by 0.9 percentage points to 22.2 per cent.
• The number of active customers rose to 12.2 million in 2025, including an increase from 10.3 million to 11.0 million in the online pharmacy[2] and from 0.9 million to 1.2 million at TeleClinic.

Segment Germany grows double-digit

• External revenue in the segment Germany grew by 11.7 per cent in local currency to CHF 1,122.5 million.
• The significant revenue drivers were Rx and Digital Services.
• Rx rose by 33.2 per cent in local currency, representing a 1.8-fold increase compared to the period before the CardLink introduction in April 2024.
• The OTC business grew by 4.8 per cent in local currency – despite the discontinuation of the Zur Rose brand in Germany at the end of 2024.
• Revenue with the core brand DocMorris increased disproportionately by more than 20 per cent.
• Digital Services, including TeleClinic, Retail Media, and Marketplace, achieved a significant positive earnings contribution with revenue growth of 110 per cent in local currency.
• Adjusted EBITDA in the segment Germany improved to minus CHF 46.3 million (previous year: minus CHF 47.2 million).
• In 2026, growth in local currency of around 20 per cent for Rx, in the mid-single-digit percentage range for OTC, and in the mid-double-digit percentage range for Digital Services is targeted.

TeleClinic achieves dynamic, profitable growth

• As Germany’s leading telemedicine platform, TeleClinic also recorded dynamic growth in 2025 with an increase of 124 per cent in local currency to CHF 25 million.
• Over 6,500 established doctors in Germany use the platform. To date, over 4 million treatments have been carried out – 2 million of which were in 2025 alone, representing an increase of over 50 per cent compared to the previous year.
• Given a telemedicine market penetration in Germany of still under 0.5 per cent, there remains substantial growth potential.
• For 2026, revenue growth in the mid-double-digit percentage range and an increase in the EBITDA margin are expected for TeleClinic.

Successful Retail Media

• With its subsidiary dmr Advertising, DocMorris has established itself as the leading healthcare retail media platform.
• In 2025, the retail media business recorded revenue in the double-digit million range with a high EBITDA margin.
• DocMorris expects continued strong, profitable growth dynamics for the coming years.

Focus on profitability and growth in the segment Europe

• DocMorris increased its revenue in the Southern European marketplace business by 1.7 per cent in local currency to CHF 63.1 million.
• Despite an increase in gross margin of 0.4 percentage points, adjusted EBITDA amounted to minus CHF 1.9 million.
• Marketing mix was further optimised, and direct procurement for more than 950 brands on the platform was consolidated.

Partnership with Google to accelerate the implementation of the “AI First” platform strategy

• DocMorris is accelerating the expansion of its AI-powered health platform through the partnership with Google (cf. press releases from DocMorris and Google dated 19 March 2026).
• The partnership focuses on four core areas: AI health companion, AI-enhanced online pharmacy, operational efficiency, as well as cloud and data security.
• In doing so, DocMorris is setting new standards for the patient journey and significantly enhancing operational performance.

Digital health and AI expert Angeli Möller joins DocMorris

• David Masó, who has been with DocMorris since 2018 and most recently served as Chief AI Health Officer, is leaving the company in April 2026 to pursue a new professional challenge. The Board of Directors and the Executive Committee thank him sincerely for his many years of valuable contribution. The Executive Committee will be reduced from six to five members.
• His duties will be assumed by Dr Angeli Möller as Chief Digital Health Officer and member of the extended Executive Committee. The PhD molecular biologist and AI expert brings extensive leadership experience from Roche and Bayer and is a co-founder of the “Alliance for Artificial Intelligence in Healthcare”.

Closure of Ludwigshafen site

• DocMorris will close the Ludwigshafen site by the end of June 2026. Logistics will be integrated into the highly automated facility in Heerlen.
• This relocation will increase efficiency, leading to a sustainable annual EBITDA improvement of over EUR 2 million from 2027 onwards.
• The closure will result in one-off, extraordinary costs of EUR 3-4 million in 2026.
• DocMorris is voluntarily making individual redundancy offers to the approximately 100 employees affected by the closure.

CO₂e emissions reduced by 49 per cent

• In 2025, DocMorris reduced CO₂e emissions by 49 per cent (Scopes 1 and 2) through several measures.
• Since 2022 (base year), the total CO₂e reduction amounts to 87.5 per cent, meaning the medium-term target of 85 per cent by 2030 has already been exceeded.
• Further measures to reduce CO₂e emissions until Net Zero is achieved are planned (see TCFD report in the annual report).

Outlook

• DocMorris has started according to plan into the new financial year.
• Management reaffirms the EBITDA break-even in the course of 2026 and the free cash flow break-even in the course of 2027, as communicated last year.
• Against this background, DocMorris provides the following guidance for 2026:
  • External revenue growth in the mid-single-digit to low teens percentage range;
  • Adjusted EBITDA of minus CHF 10 million to minus CHF 25 million;
  • Capital expenditure of around CHF 30 million.
• Medium-term targets:
  • External revenue growth rate of around 15 per cent[3] (previously 20 per cent);
  • Capital expenditure of around CHF 30 million per year (previously around CHF 35 million);
  • EBITDA margin of around 8 per cent (as before).

The annual report published today, including the integrated sustainability report, can be downloaded here.

Conference call for analysts and the media at 11 am
Speakers: Walter Hess (CEO) and Daniel Wüest (CFO)

Investors and analyst contact
Moritz Stahlhut, Investor Relations Manager
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,000 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.
 

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today’s date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.

^[1] External revenue consists of the consolidated revenue of DocMorris plus online revenues of pharmacies supplied by DocMorris, less the consolidated revenue from supplying them.

^[2] Customers supplied by DocMorris, either directly or through its partners.

^[3] Back-end loaded due to increasing relative weight of Rx and Digital Services

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract

Parties agreed to extend the maturity date of all outstanding tranches under the Finance Contract to June 28, 2028

Amendments subject to execution of definitive agreements

Milan, Italy, and Morristown, NJ, USA, March 19, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today reported that EIB and Newron have agreed to amend certain terms of the 2018 Finance Contract and Options Rights Agreement, as previously amended in 2024.

In particular, the parties agreed to extend the maturity date of all outstanding tranches under the Finance Contract to June 28, 2028. The agreement contains further terms and conditions. The agreed amendments are subject to execution by the parties of definitive agreements. Details of the 2018 Finance Contract, as amended in 2024, can be found in Newron’s 2024 Annual Report, which is posted on the Company’s website here.

Roberto Galli, Newron’s CFO, commented: “We appreciate the support of the EIB in helping us align the contractual obligations of our loan agreement to the potential timing of certain upcoming significant value inflection points presented by our lead drug candidate evenamide, which is currently developed in the global pivotal ENIGMA-TRS Phase III program for the treatment of patients suffering from treatment-resistant schizophrenia.”
 

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: www.newron.com

For more information, please contact:

Newron
Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com  

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
Paul Sagan, LaVoieHealthScience; +1 617 865 0041, psagan@lavoiehealthscience.com
 

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank 

Geneva, Switzerland – March 19, 2026 – MindMaze Therapeutics Holding SA (SIX: MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company’s shares.

Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company at CHF 3.56 per share.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company’s FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.

For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com
Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

• MDR certificate for quality management system and Class IIa products received on
  January 27, 2025
• MDR certificate for the last product group (Class IIb) successfully issued – so that MDR certificates are available for all existing products

With the MDR certificate for Class IIb products, MDR certification is completed for all existing products

aap Implantate AG (“aap” or “Company”) has received the MDR certificate for Class IIb products (plates and screws) from its Notified Body and has thus successfully completed the MDR certification process for all existing products. The transition from the previous MDD (Medical Device Directive 93/42/EEC) to the MDR (Medical Device Regulation (EU) 2017/745) is a prerequisite for the marketing of medical devices in the European Union after the expiry of the respective transition periods. With the completion of the MDR certification, the risk of missing the relevant transition periods for the existing portfolio is eliminated. At the same time, aap can secure market access in the EU as well as in CE-relevant markets in the long term. On this basis, the company is once again focusing more strongly on the further development of the portfolio and the introduction of new products. The first further developments of the LOQTEQ® product family are to be launched in the second half of 2026 and will provide positive impact for sales development from 2027 onwards.

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German Stock Exchanges –

About aap Implantate AG

aap Implantate AG is a global medical technology company headquartered in Berlin. The company develops and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the patent-protected portfolio includes a wide range of perforated screws. In addition, aap Implantate AG has an innovative pipeline of promising development projects, such as an antibacterial silver coating technology. This technology addresses critical and so far insufficiently solved problems of wound infections after surgery (SSI) in traumatology and is also applicable in other medical technological areas. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and affiliated clinics. Internationally, it mainly uses a broad network of distributors in around 41 countries. In the USA, the company and its subsidiary aap Implants Inc. rely on a network of agents and a selective direct sales strategy. The shares of aap Implantate AG are listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

There may be technical rounding differences in the figures presented in this press release, which do not affect the overall statement.

Forward-Looking Statements

This release may contain forward-looking statements based on the current expectations, assumptions and forecasts of the Management Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of future developments and results referred to therein. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial condition, development or performance of the Company to differ materially from the estimates given herein. These factors also include those described by aap in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We undertake no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Board of Directors/CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 170; Email : r.digirolamo@aap.de

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025

Planegg-Martinsried, Germany, March 18, 2026 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (the “Company”) announces that the publication of the audited 2025 annual and consolidated financial statements, originally scheduled for March 26, 2026, will be postponed.

A key reason is the change to a new internal financial planning system, which was rolled out companywide during the reporting period. Furthermore, in the course of closing process, additional reconciliation and validation work have arisen, requiring more time and documentation than originally anticipated. Against this background, not all documents have been finalized yet, and the required audit measures could not yet be completed.

The publication of the audited annual and consolidated financial statements for the 2025 fiscal year is scheduled for April 2026 and will therefore continue to comply with statutory and stock exchange deadlines. The company will announce the exact date in due course.

————-

Contact:
Formycon AG,
Fraunhoferstraße 15,
82152 Planegg/Martinsried,
Germany

Phone +49 (0) 89 – 86 46 67 149 | Fax + 49 (0) 89 – 86 46 67 110
ir@formycon.com // www.formycon.com

Disclaimer

Certain statements contained in this release may constitute “forward-looking statements” that involve a number of risks and uncertainties. Forward-looking statements can generally be identified by the use of the words “may”, “will”, “should”, “plan”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “project”, or “target” or the negative of these words or other variations of these words or comparable terminology. Forward-looking statements are based on assumptions, forecasts, estimates, predictions, opinions or plans that are inherently subject to significant risks, uncertainties and uncertainties that are subject to change. The Company makes no representation and does not make any representation that any forward-looking statement will be achieved or prove to be accurate. Actual future business, financial condition and results of operations and prospects may differ materially from those projected or projected in the forward-looking statements. Subject to applicable legal requirements, neither the Company nor any other person intends to update, review, revise or conform to actual events or developments any forward-looking statements contained in this announcement, whether as a result of the availability of new information, new developments in the future or otherwise, nor does they assume any such obligation.

Corporate News

Darwin AG launches commercialization of Multi-Cancer Check — a blood test for early detection of 13 types of cancer

Munich, March 18, 2026 – Darwin AG (ISIN DE000A3C35W0) today announced the launch of its innovative Multi-Cancer Check blood test for early cancer detection. The test was developed in collaboration with Wholomics GmbH and will initially be sold primarily through the Company’s 70% subsidiary NovoMedic GmbH. The Multi-Cancer Check is based on innovative liquid biopsy technology and multi-omics analysis with its performance data setting new standards in preventive oncology.

The Multi-Cancer Check is a non-invasive and highly specific blood test for cancer diagnosis that can detect molecular signals from several types of tumors simultaneously. Unlike many currently available liquid biopsy tests that focus on individual types of cancer, the Multi-Cancer Check allows for broad pre-screening for a total of 13 common types of cancer, including colon, uterus, ovarian, lung, and bladder cancer, thus enabling the detection of a particularly wide range of solid tumors.

In a validation study, the Multi-Cancer Check demonstrated very high sensitivity, especially in early stages of cancer, combined with excellent specificity. The test thus sets a new standard in non-invasive, blood-based early cancer detection. A total of 862 samples, including 440 confirmed cancer cases, were analyzed. The test achieved a sensitivity of 80.7% with a specificity of 99.1% and showed a sensitivity of 82.5% even in stage I. The Multi-Cancer Check produced only three false positive results.

“We are very pleased to introduce the Multi-Cancer Check, a first-class test for early cancer detection, to the market,” says CEO Dr. Daniel Wallerstorfer. “Cancer survival rates depend largely on how early the disease is detected. Our test was developed precisely for this purpose, to identify cancer with high accuracy even before symptoms appear. We are convinced that the Multi-Cancer Check, with its combination of high sensitivity in early stages and very high specificity, as well as its ability to detect different types of cancer, can make a decisive contribution to preventive medicine.”

The Multi-Cancer Check is based on a sophisticated multi-omics analysis in which more than 150 metabolites, lipoproteins, and other biomarkers are examined using nuclear magnetic resonance. The molecular signatures are evaluated using an artificial intelligence (AI) algorithm developed by cooperation partner Wholomics GmbH. The test detects common molecular signals from various solid tumors without clearly localizing the organ of origin. Positive test results should therefore be confirmed by diagnostic imaging procedures.

The global market for liquid biopsies, i.e., non-invasive biopsies or blood tests for early cancer detection and therapy monitoring, is currently estimated at around USD 7 billion and, according to market studies, is expected to grow to over USD 22 billion by 2034, corresponding to an annual growth rate of around 14%.[1] Growth is being driven in particular by the increasing use of minimally invasive or non-invasive diagnostic procedures such as liquid biopsies, which offer significant advantages over traditional tissue biopsies and are therefore increasingly being used in cancer detection and treatment. Compared to traditional tissue biopsies, non-invasive liquid biopsies offer the advantage of fewer complications, ease of repetition, and the ability to map tumor changes in real time. They can provide important molecular information about a tumor, especially in cases of hard-to-reach cancers, making the different biological characteristics of tumors more visible and enabling physicians to make more targeted, personalized treatment decisions.

About Darwin AG

The “Darwin Group” (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European healthcare company, particularly active in the field of human genetics and the development of personalized products based on genetic analysis. The genetic analyses conducted in the company’s own laboratory are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Darwin also acts as a partner to physicians, therapists, pharmacists, nutritionists, and fitness trainers, helping to ensure treatment or support that is as optimal as possible for the patient’s or client’s needs by analyzing their respective genetic predispositions. In addition, Darwin holds investments in innovative companies in the biotech, healthcare, and life sciences sectors. More information: https://darwin-biotech.com/

^[1] Precedence Research, Liquid Biopsy Market Size, Share and Trends 2025 to 2034

Contact: